RNAGene announced today that it has signed a collaborative research agreement with PharmAbcine. Under the agreement, both companies will collaborate to develop next-generation mRNA-based antibody therapeutics by utilizing the proprietary mRNA platform from RNAGENE.

Unlike the existing antibody treatments, in which antibodies are artificially produced from external cell lines, mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody.

"The company entered this agreement because this partnership gives us an extraordinary opportunity to expand our development strategy and discover new possibilities in the mRNA therapeutic area," said Dr. Jin-San Yoo, CEO of PharmAbcine. "Through this collaboration, both parties will explore new potentials between the two platforms and develop a new therapeutic approach to help patients with unmet medical needs."

"One of the key strengths of mRNA therapy is that it is simple and cost-effective because there is no need to produce antibodies externally in a facility," said Dr. Woo Gil Lee, CEO of RNAGene. "We are delighted to have PharmAbcine, one of the leading antibody-based therapeutic companies, as a partner for this collaborative research, and we are confident that our advanced mRNA technology platform will help create alternative therapeutic options in oncology field."